Tumors can evade the immune system by upregulating checkpoint proteins such as PD-L1 and CTLA-4. When these proteins bind to their respective receptors on T-cells, they send inhibitory signals that reduce T-cell activity. This allows cancer cells to proliferate unchecked because the immune system is essentially "turned off." Understanding this mechanism has led to the development of immune checkpoint inhibitors as a therapeutic strategy in cancer treatment.
